{"disease":{"id":"ovary","name":"ovary"},"drugs":{"marketed":[{"drug_id":"olaparib","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynparza","generic_name":"olaparib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor [EPC]","quality_score":73,"revenue":"2600","mechanism":"Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP."},{"drug_id":"olaparib","indication_name":"Epithelial tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynparza","generic_name":"olaparib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor [EPC]","quality_score":73,"revenue":"2600","mechanism":"Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP."},{"drug_id":"bevacizumab","indication_name":"Malignant epithelial tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"cyclophosphamide","indication_name":"Adenocarcinoma of the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"niraparib","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zejula","generic_name":"niraparib","company_name":"GSK","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":69,"revenue":"600","mechanism":"Zejula works by blocking the action of an enzyme called PARP, which helps repair damaged DNA in cancer cells."},{"drug_id":"niraparib","indication_name":"Malignant epithelial tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zejula","generic_name":"niraparib","company_name":"GSK","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":69,"revenue":"600","mechanism":"Zejula works by blocking the action of an enzyme called PARP, which helps repair damaged DNA in cancer cells."},{"drug_id":"nab-paclitaxel","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"nabpaclitaxel","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"paclitaxel","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"zirabev","indication_name":"Malignant epithelial tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"vintafolide","indication_name":"Malignant epithelial tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vynfinit","generic_name":"VINTAFOLIDE","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"vintafolide","quality_score":0,"revenue":null,"mechanism":"Vynfinit works by binding to folate receptor beta, which is overexpressed in certain cancer cells, and delivering a toxic payload to these cells."},{"drug_id":"topotecan","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nogitecan","generic_name":"topotecan","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"topotecan","quality_score":80,"revenue":null,"mechanism":"Topotecan is a topoisomerase inhibitor that prevents DNA re-ligation, causing double-strand DNA damage."},{"drug_id":"alkeran","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alkeran","company_name":"French Innovative Leukemia Organisation","drug_phase":"phase_2","molecular_target":"L-type amino acid transporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"adriacin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hycamtin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hycamtin","company_name":"North Eastern German Society of Gynaecological Oncology","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 4, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Adenocarcinoma of the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tretamine","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"tretamine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lynparza","indication_name":"Epithelial tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lynparza","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"lynparza","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lynparza","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"gemcitabine","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gemzar","generic_name":"gemcitabine","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"DNA polymerase (alpha/delta/epsilon)","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":75,"revenue":null,"mechanism":"Gemzar works by mimicking a building block of DNA, tricking cancer cells into incorporating it into their DNA and then stopping the replication process."},{"drug_id":"altretamine","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hexalen","generic_name":"ALTRETAMINE","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Cytochrome P450 1A2","drug_class":"Alkylating Drug","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"melphalan","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alkeran","generic_name":"melphalan","company_name":"Apotex","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"chembl-chembl1200796","indication_name":"Adenocarcinoma of the ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"hydroxycarbamide","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamide","company_name":"University of Birmingham","drug_phase":"phase_3","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"siklos","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Siklos","company_name":"Theravia","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"paraplatin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Paraplatin","company_name":"ARCAGY/ GINECO GROUP","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"taxol","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xromi","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xromi","company_name":"Nova Laboratories Limited","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"clomiphene","indication_name":"Polycystic Ovary Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CLOMIPHENE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"hydroxycarbamid","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamid","company_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","drug_phase":"phase_2","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gemcitabin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gemcitabin","company_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","drug_phase":"marketed","molecular_target":"UMP-CMP kinase, Deoxycytidine kinase, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"belotecan","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camtobell","generic_name":"BELOTECAN","company_name":"Chong Kun Dang","drug_phase":"marketed","molecular_target":"DNA topoisomerase 1","drug_class":"belotecan","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avastin","indication_name":"Malignant epithelial tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"yondelis","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yondelis","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"trabectedin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yondelis","generic_name":"TRABECTEDIN","company_name":"Janssen Prods","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Yondelis works by binding to DNA and causing interstrand crosslinks, thereby inhibiting cancer cell growth."},{"drug_id":"gemcitabine-hydrochloride","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gemzar","generic_name":"Gemcitabine Hydrochloride","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase; DNA incorporation","drug_class":"Nucleoside metabolic inhibitor","quality_score":69,"revenue":null,"mechanism":"Gemcitabine kills cells during DNA synthesis and blocks G1/S-phase progression."},{"drug_id":"carboplatin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Paraplatin","generic_name":"Carboplatin","company_name":"MYLAN SEIYAKU Ltd","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Platinum-containing alkylating agent","quality_score":10,"revenue":null,"mechanism":"Carboplatin produces predominantly interstrand DNA cross-links in a cell-cycle nonspecific manner."},{"drug_id":"cisplatin","indication_name":"Malignant tumor of ovary","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Platinol-Aq","generic_name":"cisplatin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Platinum-based Drug [EPC]","quality_score":52,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":51,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06124391","title":"Novel Subtypes of Polycystic Ovary Syndrome","phase":"","overall_status":"UNKNOWN","enrollment_count":50000,"lead_sponsor_name":"Shandong University","has_results":false},{"nct_id":"NCT06115122","title":"PEPPI Study: Identification of Women at Risk for Placental Dysfunction","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Oulu University Hospital","has_results":false},{"nct_id":"NCT06047574","title":"Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Shanghai 10th People's Hospital","has_results":false},{"nct_id":"NCT04916171","title":"Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis","phase":"","overall_status":"UNKNOWN","enrollment_count":2450,"lead_sponsor_name":"Kanuni Sultan Suleyman Training and Research Hospital","has_results":false},{"nct_id":"NCT05527353","title":"AMH for the Identification of PCOM in PCOS Diagnosis","phase":"","overall_status":"UNKNOWN","enrollment_count":1800,"lead_sponsor_name":"Oulu University Hospital","has_results":false},{"nct_id":"NCT05463627","title":"Effects of Metformin on Metabolic and Reproductive Outcomes in Chinese PCOS Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":1440,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03618342","title":"Serum Metabolomics Study of Polycystic Ovary Syndrome","phase":"","overall_status":"UNKNOWN","enrollment_count":1272,"lead_sponsor_name":"Heilongjiang University of Chinese Medicine","has_results":false},{"nct_id":"NCT05177562","title":"Reproductive Endocrinology Oxford Study (RepOx)","phase":"","overall_status":"RECRUITING","enrollment_count":1175,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT03625531","title":"A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1103,"lead_sponsor_name":"Hongxia Ma","has_results":false},{"nct_id":"NCT02607293","title":"A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation","phase":"","overall_status":"COMPLETED","enrollment_count":1064,"lead_sponsor_name":"Merck KGaA, Darmstadt, Germany","has_results":false},{"nct_id":"NCT03911297","title":"DAISy-PCOS Phenome Study - Dissecting Androgen Excess and Metabolic Dysfunction in Polycystic Ovary Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT01573858","title":"Acupuncture and Clomiphene Citrate on Live Birth in Anovulatory Women With Polycystic Ovary Syndrome","phase":"NA","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Heilongjiang University of Chinese Medicine","has_results":false},{"nct_id":"NCT04401592","title":"The Role of Galectins in the Non-invasive Diagnosis of Endometriosis","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Semmelweis University","has_results":false},{"nct_id":"NCT04082650","title":"Vitamin D and Pregnancy Outcome in PCOS Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":876,"lead_sponsor_name":"Women's Hospital School Of Medicine Zhejiang University","has_results":false},{"nct_id":"NCT02997553","title":"Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":744,"lead_sponsor_name":"Institut de Cancérologie de Lorraine","has_results":false},{"nct_id":"NCT04264832","title":"Body Fat Distribution and Its Associated Factors in Chinese Women With Polycystic Ovary Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":733,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT05106712","title":"Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women","phase":"NA","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"Umm Al-Qura University","has_results":false},{"nct_id":"NCT07068464","title":"ICRA Randomised Controlled Trial","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":682,"lead_sponsor_name":"NHS Grampian","has_results":false},{"nct_id":"NCT06601452","title":"Clinical Trial of Anovulatory Infertility","phase":"EARLY_PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":650,"lead_sponsor_name":"Affiliated Hospital of Nanjing University of Chinese Medicine","has_results":false},{"nct_id":"NCT05926115","title":"Phenotype and Epidemiology of the Polycystic Ovary Syndrome (PCOS) in Colombia (PEP - Colombia) Study.","phase":"","overall_status":"UNKNOWN","enrollment_count":626,"lead_sponsor_name":"Instituto de fertilidad humana, InSer","has_results":false},{"nct_id":"NCT04000880","title":"Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":603,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT05063383","title":"Analysis of Clinical Characteristics and Study of Diagnostic Markers in Patients with Polycystic Ovary Syndrome","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Shanghai 10th People's Hospital","has_results":false},{"nct_id":"NCT07171970","title":"IVM - Fresh ET (THE SAIGON PROTOCOL) Versus IVF - FET in PCOS Women","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Mỹ Đức Hospital","has_results":false},{"nct_id":"NCT06331130","title":"Mesenteric Infiltration in Ovarian Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":510,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT02010814","title":"Characterization of a Prospective Cohort of Women With PCOS","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT06405178","title":"Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT07499518","title":"Fertility and Polycystic Ovary Syndrome","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":473,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05256576","title":"KORE-INNOVATION: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients with Ovarian Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":465,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT06545721","title":"Weight Cycling on Hyperandrogenemia and Insulin Resistance in Polycystic Ovary Syndrome","phase":"NA","overall_status":"RECRUITING","enrollment_count":425,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06729359","title":"Polycystic Ovary Syndrome and Urinary Tract Stones: a BMI-Adjusted Analysis in Iraqi Women","phase":"","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Al-Kindy College of Medicine","has_results":false},{"nct_id":"NCT06049186","title":"CRD vs. Met in Patients With Obese PCOS Infertility","phase":"NA","overall_status":"UNKNOWN","enrollment_count":406,"lead_sponsor_name":"Shanghai First Maternity and Infant Hospital","has_results":false},{"nct_id":"NCT04406597","title":"Safety, Effectiveness and Operability of Using the New Tissue Containment System During Laparoscopic Ovarian Cystectomy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT05976529","title":"A Multicenter, Observational Clinical Study of Dydrogesterone","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Guangdong Women and Children Hospital","has_results":false},{"nct_id":"NCT06192147","title":"The Phenotype and Clinical Intervention of High BCAA Type of PCOS","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT07394530","title":"Comparison of IVF Outcomes Between PPOS and Antagonist Protocols in Women With PCOS","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Hanoi General Hospital (Vietnam)","has_results":false},{"nct_id":"NCT06543225","title":"Awareness Of Gynecologists About Role Of Physical Therapy In Management Of Polycystic Ovarian Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":399,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT07213193","title":"No-Stoma Policy in Advanced Ovarian Cancer Surgery","phase":"NA","overall_status":"RECRUITING","enrollment_count":395,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06775093","title":"Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":392,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06969833","title":"Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":371,"lead_sponsor_name":"Centre Oscar Lambret","has_results":false},{"nct_id":"NCT03842982","title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":362,"lead_sponsor_name":"Centre Oscar Lambret","has_results":false},{"nct_id":"NCT04534075","title":"Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT06339567","title":"Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":352,"lead_sponsor_name":"Fondation Hôpital Saint-Joseph","has_results":false},{"nct_id":"NCT07016035","title":"Translation and Validation of the French mPCOSQ (mPCOSQ-F).","phase":"","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT04532645","title":"Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK","phase":"","overall_status":"COMPLETED","enrollment_count":342,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04178018","title":"Transvaginal Ultrasound and Photoacoustic Imaging of Ovary","phase":"NA","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT07441811","title":"Urine Albumin/Creatinine Ratio and Renal Function Differences in Phenotypes of Polycystic Ovary Syndrome.","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Uşak University","has_results":false},{"nct_id":"NCT06358300","title":"Visceral Adiposity Index Differences Between Subtypes of Polycystic Ovary Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Uşak University","has_results":false},{"nct_id":"NCT05763511","title":"Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05937360","title":"Prevalence of Polycystic Ovary Syndrome In Trinidad","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"The University of The West Indies","has_results":false},{"nct_id":"NCT05782725","title":"Subclinical Hypothyroidism and Normogonadotropic Anovulation","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Jagiellonian University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}